DUSA Pharmaceuticals Announces Orphan Drug Designation for Levulan(R) PDT Has Received FDA Approval.

0 Comments | M2 Presswire, May, 2007

M2 PRESSWIRE-17 May 2007-Making The Watchlist: DUSA Pharmaceuticals Announces Orphan Drug Designation for Levulan(R) PDT Has Received FDA Approval(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:17052007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets.

Activity on the NASDAQ market has brought this company to the attention of our research team. DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. May 17th - DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announced...